Table 2.
Summary of pharmacokinetic parameters of ethinyloestradiol and levonorgestrel.
| Pharmacokinetic parameter | Oral contraceptive with placebo (n =18) | Oral contraceptive with ziprasidone (n =18) | Ratio (AUC and Cmax) or difference (tmax) | 95% confidence limits |
|---|---|---|---|---|
| Ethinyloestradiol | ||||
| AUC(0,24 h)a, c (pg ml−1 h) | 971 ± 225 | 964 ± 204 | 99.3% | 93.9,105.1 |
| Cmaxa (pg ml−1) | 77.1 ± 25.6 | 72.4 ± 22.9 | 93.9% | 85.6,103.0 |
| tmaxb (h) | 2.3 ± 1.2 | 2.9 ± 1.3 | 0.6 | −0.2,1.3 |
| Levonorgestrel | ||||
| AUC(0,24 h)a, c (ng ml−1 h) | 87.7 ± 23.7 | 85.7 ± 25.3 | 97.8% | 92.8,103.0 |
| Cmaxa (ng ml−1) | 6.42 ± 2.00 | 5.95 ± 1.86 | 92.7% | 84.5,101.8 |
| tmaxb (h) | 1.7 ± 1.0 | 2.3 ± 1.1 | 0.6 | 0.1,1.3 |
a
Geometric means and s.d. for AUC(0,24 h) and Cmax.
b
Arithmetic means and s.d. for tmax.
c
Excludes two subjects. One of these subjects had plasma ethinyloestradiol concentrations below the limit of detection 24 h after taking ziprasidone and one had plasma ethinyloestradiol concentrations below the limit of detection at 18 and 24 h after taking ziprasidone.